title: Switching between antitumour necrosis factor alpha biologic agents--is patient weight an important consideration?
authors.forename: A M R
authors.initials: AM
authors.lastname: Downs
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D015992:Body Mass Index; D001835:Body Weight; D003879:Dermatologic Agents / Q000008:administration & dosage*; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage*; D000069285:Infliximab; D008297:Male; D011565:Psoriasis / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage*; D017211:Treatment Failure; D014409:Tumor Necrosis Factor-alpha
chemical_list: D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept